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Background: The chemokine receptor CCR7 mediates lymphoid dissemination of many cancers, including
lymphomas and epithelial carcinomas, thus representing an attractive therapeutic target. Previous results have
highlighted the potential of the anti-CCR7 monoclonal antibodies to inhibit migration in transwell assays. The
present study aimed to evaluate the in vivo therapeutic efficacy of an anti-CCR7 antibody in a xenografted human
mantle cell lymphoma model.
Methods: NOD/SCID mice were either subcutaneously or intravenously inoculated with Granta-519 cells, a human
cell line derived from a leukemic mantle cell lymphoma. The anti-CCR7 mAb treatment (3 × 200 μg) was started on
day 2 or 7 to target lymphoma cells in either a peri-implantation or a post-implantation stage, respectively.
Results: The anti-CCR7 therapy significantly delayed the tumor appearance and also reduced the volumes of tumors
in the subcutaneous model. Moreover, an increased number of apoptotic tumor cells was detected in mice
treated with the anti-CCR7 mAb compared to the untreated animals. In addition, significantly reduced number of
Granta-519 cells migrated from subcutaneous tumors to distant lymphoid organs, such as bone marrow and
spleen in the anti-CCR7 treated mice. In the intravenous models, the anti-CCR7 mAb drastically increased survival
of the mice. Accordingly, dissemination and infiltration of tumor cells in lymphoid and non-lymphoid organs,
including lungs and central nervous system, was almost abrogated.
Conclusions: The anti-CCR7 mAb exerts a potent anti-tumor activity and might represent an interesting thera-
peutic alternative to conventional therapies.Background
The metastatic spread of cancers takes place when neo-
plastic cells leave the anatomic boundaries of the affected
organ. Conversely, the dissemination of lymphomas does
not always reflect the progression of the tumor, but reca-
pitulates the so-called homing signature of normal lymph-
oid cells, which is characterized by a conserved pattern of
migration and recirculation [1,2]. This particular tissue
tropism explains the rapid dissemination of lymphomas
and the different patterns of tissue infiltration of the* Correspondence: cmunozc@salud.madrid.org
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oid organs, whose microenvironment provides prolifer-
ative and survival signals to the tumor cells, become
authentic sanctuaries for lymphoid malignancies [3,4].
Thus, controlling the lymphoma dissemination repre-
sents one of the unresolved therapeutic challenges in
this type of neoplasia [5,6].
Homing of normal lymphoid cells is a multistep
process that requires chemotaxis, cell adhesion, and
extravasation of lymphocytes across the vessel wall. This
process is regulated by adhesion molecules and chemo-
kine receptors on the surface of the lymphocytes, and
their ligands expressed by the endothelial cells [7,8]. CC-
chemokine receptor 7 (CCR7) is a well-characterizedd Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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memory lymphocytes and mature dendritic cells and this
allows these cells to respond to the ligands of CCR7, the
homeostatic chemokines CC-chemokine ligand 21 (CCL21)
and CCL19, produced in secondary lymphoid organs (SLO)
[9]. CCR7 is required for the entry of normal T and B lym-
phocytes through the endothelium of high endothelial ve-
nules into the SLO, including lymph nodes and Peyer’s
patches [10,11]. Consistent with their lymphoid origin,
many leukemias and lymphomas express CCR7 [12-16]. In-
deed, results from our laboratory have demonstrated that
CCR7 plays a major role in the migration and nodular dis-
semination of certain lymphoproliferative syndromes in-
cluding chronic lymphocytic leukemia (CLL) and mantle
cell lymphoma (MCL) [12]. In addition, CCR7 also plays a
significant role in the lymph node dissemination of those
epithelial solid tumors that ectopically express this chemo-
kine receptor [17]. Furthermore, CCR7 has been also impli-
cated in acute T-cell leukemia infiltration of the central
nervous system (CNS) [18].
Therefore, the blockage of CCR7-mediated migration
might represent a new therapeutic approach for the
treatment of certain lymphoproliferative disorders. In
this regard, we previously demonstrated that anti-CCR7
antibodies and different chemical inhibitors of the sig-
naling pathways activated by CCR7 efficiently blocked
in vitro migration of primary CLL cells in response to
the CCR7 ligands. Moreover, our results also showed
that anti-CCR7 antibodies induced potent in vitro Fc-
mediated complement-dependent cytotoxicity [19,20].
These in vitro findings have led us to investigate the
in vivo efficacy of anti-CCR7 therapy. Among the dif-
ferent CCR7-expressing hematological tumors, we de-
cided to study the benefits of an anti-CCR7 mAb on MCL
due to the limited therapeutic options and an unmet need
of alternative treatments for this hematologic disorder
[21-23]. MCL is an aggressive B-cell malignancy that ac-
counts for approximately 6% of all non-Hodgkin lymphoma
(NHL) cases diagnosed every year. Current therapies in-
clude chemo-immunotherapy or high dose chemotherapy
followed by autologous stem cell transplantation. Although
conventional chemotherapy induces high-remission rates in
previously untreated patients, relapse within a few years is
common, contributing to a rather short median survival of
5–7 years [24,25]. In this regard, mAbs represent ideal al-
ternative options for heavily pretreated patients with relapse
and/or refractory MCL because their limited toxicity and
the improvement of patient outcomes when combined with
chemotherapy [26]. Interestingly, a recent meta-analysis in-
dicated that the addition of rituximab to the conventional
chemotherapy may increase the overall survival when com-
pared with chemotherapy [27].
We hereby show that the treatment of MCL-xenografted
mice with an anti-CCR7 mAb significantly increased thesurvival of the animals. The increased survival was due to
both decreased infiltration of MCL cells into different tis-
sues and to the induction of MCL cells cytotoxicity in the
mice. In summary our results support that anti-CCR7 im-
munotherapy might be an option for the treatment of
MCL and other CCR7+ lymphoproliferative disorders.
Methods
Cells and culture
Granta-519 human mantle cell lymphoma (MCL) cell line
was purchased from the German Collection of Microorgan-
isms and Cell Cultures (DSMZ) repository (Braunschweig,
Germany). Cells were cultured at 0.5-2.0 × 106 cell/ml in
RPMI-1640 supplemented with 10% (v/v) fetal calf
serum (FCS), 2 mM L-glutamine, 100 unit/ml penicillin
and 0.1 mg/ml streptomycin. Experiments with human
specimens were approved by the ethics committee of
the Hospital de la Princesa. Human samples were ob-
tained from healthy donors and from patients with dif-
ferent B-cell neoplasms after informed consent. Human
peripheral blood (PB) and bone marrow (BM) aspirates
were obtained by venipuncture and sternun puncture, re-
spectively, and peripheral blood mononuclear cells (PBMC)
were separated by ficoll density gradient centrifugation.
Murine splenocytes were obtained from NOD/SCID
and NSG mice by splenectomy and separated by ficoll
density gradient centrifugation.
Reagents
Mouse anti-human CCR7 mAb (150503 clone, IgG2a
isotype) was obtained from R&D Systems (Minneapolis,
MN, USA) and was resuspended in sterile water.
Alemtuzumab was obtained from the department of
pharmacy at our hospital.
For flow cytometric analysis, mouse anti-human CD19
mAb (fluorescein isothiocyanate; FITC), mouse anti-human
CD20 mAb (Pacific Blue; PB), mouse anti-human CCR7
mAb (Phycoerythrin; PE) and the DNA dye 7-Actinomycin-
D (7-AAD) were purchased from Becton Dickinson (BD)
Biosciences (San José, CA, USA).
CCR7 expression
CCR7 expression in Granta-519 cells was assessed by
flow cytometry. Briefly, 1 × 106 Granta-519 cells were
washed twice with cold PBS, resuspended in 100 μl cold
PBS, incubated with the PE-conjugated anti-human
CCR7 mAb for 15 minutes and washed with PBS. An
appropriate isotype control was included in the analysis.
For staining of primary samples, 100 μl whole PB
or BM samples were incubated for 15 minutes at room
temperature with PE-conjugated anti-human CCR7
mAb. This incubation was followed by the lysis of
red blood cells by using ammonium chloride lysing
solution (BD Biosciences) following the manufacturer’s
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500 μl cold PBS. Data acquisition and analysis were
performed on a FACSCanto II flow cytometer using the
DIVA software (BD Biosciences). In all experiments, a
minimum of 5000 neoplastic B cells was acquired. Re-
sults are expressed as the percentage of CCR7 positive
cells and mean fluorescence intensity (MFI) of CCR7
expression.
Transwell assays
Chemotaxis of Granta-519 cells in response to CCL19 and
to CCL21 was assayed in Transwell cell culture chambers
(6.5 mm diameter, 10 μm thickness, 5 μm diameter pore
size, Costar, Cambridge, MA). When required, cells were
preincubated for 30 min with 2 μg/ml anti-CCR7 mAb.
Briefly, 5 × 105 Granta-519 cells, resuspended in 100 μl
RPMI-1640 medium with 0.5% bovine serum albumin
(BSA), were added to the upper compartment of the
chamber, and chemokines were added to the lower well in
600 μl of the same medium at the optimal concentration
(1 μg/ml for both CCL19 and CCL21). Migration was
allowed to proceed for 4 h at 37°C in 5% CO2 atmosphere.
Migrated cells were recovered from the lower chamber
and counted by flow cytometry for 60 s after calibrating
the flow rate with Trucount tubes (BD Biosciences).
Events were compared with the number of cells counted
in the initial suspension of cells to calculate the percentage
of input (100 × number of cells migrated/number of cells
counted in the initial suspension). Each experiment was
performed in duplicate.
Complement-dependent cytotoxicity (CDC)
1 × 105 Granta-519 cells (50 μl) were seeded in a 96-well
round-bottom plate together with 2 μg/ml of either puri-
fied anti-human CCR7 mAb or the corresponding isotype
control (IC). After 30 min incubation at 37°C, the cells
were centrifuged and washed. Then, baby rabbit comple-
ment (Serotec, Oxford, UK), diluted at the concentration
indicated by the manufacturer (25%) in RPMI-1640
medium was added. After 1–2 h at 37°C, the cells were
stained with fluorescein isothiocyanate (FITC)-conjugated
anti-CD19 mAb and PB conjugated anti-CD20 mAb and
with 7-AAD as a viability exclusion dye. The percentage
of non-viable cells was measured and the percentage of
lysis with heat-inactivated complement was used to calcu-
late the specific lysis with the formula: Specific lysis (%) =
100 × (% dead cells with complement –% dead cells with
inactivated complement) / (100–% dead cells with inacti-
vated complement).
Antibody-dependent cell-mediated cytotoxicity (ADCC)
ADCC assays were performed using Granta-519 cell line
as target cells and either human PBMC or murinesplenocytes as effectors cells. The target to effector ratio
was 1:10 in both cases.
Granta-519 cell were washed and resuspended at 1 ×
106 cells/ml in PBS containing 5 μg/ml calcein-UV Cell
Tracker (Invitrogen, OR, USA) and incubated at 37°C
for 30 minutes. Cells were then washed twice and resus-
pended in RPMI-1640 supplemented with 10% FCS, in
presence or absence of 100 μg/ml of either isotype con-
trol, anti-CCR7 mAb, or alemtuzumab for 30 minutes.
Granta-519 cells were washed again and 1 × 105 cells
were plated with human PBMC or murine splenocytes.
After 24 hours, the cells were stained with 7-AAD and
analyzed by flow cytometry (FACSCanto II, BD Biosci-
ences). The percentage of Granta-519 cells killed by
antibody-mediated cytotoxicity was calculated substract-
ing the percentage of dead cells in the presence of con-
trol isotype mAb.
Mice
NOD/SCID and NSG female mice were housed in the ani-
mal facility of the Instituto de Investigaciones Biomédicas
“Alberto Sols” and in the facilities of Vivotecnia, under
standard sterile conditions in air-filtered containers, ac-
cording to protocols approved by European directives and
Spanish laws (European Directives 86/609/EEC/2003/65/
EC Spanish Law RD 1201/2005). NSG mice were from
Charles River (Barcelona, Spain). The in vivo expe-
rimental procedures were approved by the pertinent
ethic committees and carried out in accordance with
the guidelines of the European directives and Spanish
laws.
Only those animals that met the inclusion criteria
(20% of the mean body weight) were included in the
study and distributed into the different experimental
groups according to the body weight stratification
method.
In vivo anti-tumor activity of anti-human CCR7 mAb in
NOD/SCID mice
To evaluate the anti-tumor efficacy of the anti-human
CCR7 mAb, NOD/SCID mice were xenografted with the
Granta-519 human MCL cell line. All mice used in the
experiment were females and were 8 ± 1 weeks old.
We have used two inoculation vias: (1) cells were sub-
cutaneously injected resulting in a localized tumor and
(2) cells were intravenously injected resulting over time
in a disseminated lymphoma.
The subcutaneous model was developed by inoculating
a group of 5 mice with 5 × 106 viable cells subcutane-
ously (in the right hind flank). The number of inoculated
cells to establish the subcutaneous model was chosen on
the basis of previous experiments to determine the num-
ber of Granta-519 cells required to develop palpable tu-
mors in the mouse in around one week.
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treatment model of the lymphoma and therefore the
mice were intraperitoneally injected with 200 μg anti-
human CCR7 mAb two days after inoculation of
Granta-519 cells. This treatment was repeated on day 6
and 10. As a control group we inoculated a group of 5
mice with sterile PBS on days 2, 6 and 10.
The disseminated model involved inoculating mice
intravenously (in the tail vein) with 0.5 × 106 cells. The
number of Granta-519 cells inoculated in the intraven-
ous model was chosen on the basis of previous experi-
ments done to establish the number of Granta-519 cells
that resulted in the development of visible signs of dis-
ease in a period of around 40–60 days. This model was
split into two branches, a “peri-implantation” model, de-
fined as the period in which tumor cells are circulating
and not yet located in the target organs, in which mice
were treated 2 days after the xenograft, and a “post-
implantation” model, in which surviving tumor cells are
expected to have reached their target organs. In this
model mice were treated 7 days after the xenograft. The
peri-implantation model included a group of 5 mice
treated with 200 μg anti-human CCR7 mAb intraperito-
neally on days 2, 6 and 10. A control group of 5 mice
were inoculated with PBS on the same days of 2, 6 and
10. The post-implantation model involved 3 groups of
mice. A group of 5 mice were inoculated with 200 μg
anti-human CCR7 mAb intraperitoneally on days 7, 11
and 15. A second group of 5 mice were a control group
inoculated with 200 μg of an isotype control intraperito-
neally on days 7, 11 and 15. And a third group also a
control group that received sterile PBS inoculated on
days 7, 11 and 15. Mice were weighted every three days
and checked for any signs of pathologies, discomfort or
mortality, according to the OCDE Humane Endpoints
Guidance Document.
The length and width of the tumors in the subcutane-
ous model were measured with a caliper three times per
week or when deemed necessary once the tumor lenght
was ≥ 4 mm. The largest (D) and shortest (d) diameters
of the tumor were measured every third day and the
tumor volume was calculated according to the formula:
V =D * d2/2. The growth inhibitory rate (IR) was calculated
by the formula: IR(%) = 100 ‐ [(V1/V2)] * 100, wherein V1
is the mean tumor volume in the mAb treated group, and
V2 is the mean tumor volume in the control group. Ani-
mals bearing tumors with D ≥ 15 mm or with signs of
ulceration were sacrificed for humane reasons.
The in vivo experiments in the subcutaneous model
continued until two mice in a group developed tumor
size with D ≥ 15 mm. This was observed on day 27 in
the control group. Since the ethical protocol requires
that these two mice should be sacrificed we decided to
sacrifice all the mice to perform a comparative study.Mice were euthanized and the tumors and organs
(spleen, bone marrow, brain, lungs, liver, small intestine,
ovaries and spine) were harvested and weighed. Organs
were fixed in 4% neutral buffered formaldehyde for histo-
chemistry analysis whereas a piece of fresh spleen and the
bone marrow were conserved in PBS at 4°C for flow cy-
tometry assays. Subcutaneous tumors were divided in two:
one half was fixed in 4% neutral buffered formaldehyde
for histochemistry analysis and the other half was con-
served in PBS at 4°C for flow cytometry assays. In the
intravenous model, mice were euthanized when they de-
veloped incipient signs of limb paralysis, approximately
6–9 weeks after the inoculation of the lymphoma cells.
In order to evaluate potential toxic effects of the anti-
human CCR7 mAb, a third group of 3 mice were not
inoculated with tumor cells but treated with the anti-
human CCR7 mAb following the same administration
regimen than that of the treated xenografted mice.
Flow cytometric cell analysis
Spleens and tumors were mechanically disaggregated.
Cells were harvested and washed twice in cold PBS. Red
cells were lysed using ammonium chloride solution (BD
Biosciences), and then the remaining cells were washed
twice with cold PBS, resuspended in binding buffer (BD
Biosciences), and counted. One million cells from the
spleen, bone marrow or tumors were incubated with PB
anti-human CD20 mAb (clone 2H7, specific for human B
cells, non cross reacting with murine lymphoid cells) in
50 μl of blocking solution (PBS, 2% BSA) for 15 minutes.
The appropriate isotype control was included in the ana-
lysis. Analysis was performed on a FACSCanto II flow cyt-
ometer using the DIVA software (BD Biosciences).
Apoptosis assay (viability assays)
The Annexin-V-FITC assay (BD Biosciences) was used ac-
cording to the manufacturer’s instructions to quantitatively
determine the percentage of non-viable cells following
exposure to anti-human CCR7 mAb. Briefly, tumor cells
were harvested and resuspended in binding buffer (BD
Biosciences). 100 μl of the cell suspension was stained with
Annexin-V-FITC. After 10 minutes, 0.4 ml of binding buf-
fer and 10 μl of 7-AAD were added, and the cells were ana-
lyzed immediately by flow cytometry. Early apoptotic cells
were defined as Annexin-V+/7-AAD-, late apoptotic cells
as Annexin-V+/7-AAD+, dead cells as Annexin-V-/7-AAD+
and viable cells as Annexin-V-/7-AAD-.
Immunohistochemistry
Organs and tissues extracted from mice were fixed in 4%
formalin, dehydrated through grades of ethanol in a
Microm STP 420D sample processor (Thermo Scientific,
Kaklamazoo MI, USA), embedded in paraffin in EC 350–1
paraffin station (Myr, El Vendrell, Tarragona, Spain) and
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chemistry, the antigen retrieval was performed with citrate
pH 6 in microwave. Slides were stained with anti-human
CD20 antibody (clone L26, Roche) by using the VENTANA
BenchMark ULTRA System (Roche).
Statistical analysis
Statistical significance between untreated and treated
samples was assessed with Student’s t test for unpaired
data (two tail). Differences were considered significant if
P-values were < 0.05. Survival data were analyzed by the
Kaplan-Meier method and the Tarone-Ware test was
used to test for significance among all the groups.
Results
Anti-CCR7 mAb blocks migration of mantle cell lymphoma
cells in response to CCL19 and CCL21 in vitro and mediates
CDC and ADCC
CCR7 is expressed in different primary lymphoprolifera-
tive disorders as we and others have previously demon-
strated (12–18). In this study, we have confirmed and
extended these results in a larger cohort of patients. Our
results show that tumor cells from CLL and MCL patients
consistently express CCR7 on the cell surface and at
high density, compared to other lymphoproliferative syn-
dromes. Other lymphomas such as follicular lymphomas
or lymphoplasmacytic lymphomas also contain tumor
populations expressing CCR7 but mixed with CCR7-
negative tumor cells (see Additional file 1: Figure S1).
Therefore, CCR7 may represent a new therapeutic target
for the treatment of certain hematological cancers, in
particular MCL and CLL.
To assess the ability of anti-CCR7 antibodies to inhibit
in vitro migration of MCL cells towards the ligands
of CCR7, the homeostatic chemokines CCL19 and
CCL21, we used the CCR7-positive Granta-519 MCL
cell line (Figure 1A). As shown in Figure 1B, we demon-
strated in transwell chamber assays that anti-CCR7 mAb
(clone 150503) was very efficient in preventing Granta-
519 cells chemotactic response to CCL19 or CCL21. An-
other anti-CCR7 mAb (clone2H4, IgM) was also able to
partially block Granta-519 migration, albeit less effectively
than clone 150503 (data not shown).
The ability of the anti-human CCR7 antibodies to in-
duce CDC or ADCC in MCL cells was also evaluated in
the MCL cell line Granta-519. To perform the CDC ex-
periments, the cells were preincubated with two different
clones of the anti-CCR7 antibody or with the correspond-
ing isotype control (IC) for 1 hour and incubated with
rabbit complement during an additional hour. The anti-
CCR7 clone 150503 induced a two-fold induction in CDC
when compared with the control antibody (Figure 1C).
The ADCC experiments were performed with human
PBMC and Granta-519 cells as targets in the presence ofeither IC antibody, the anti-CCR7 mAb or alemtuzumab,
a therapeutic antibody known to mediate ADCC. We con-
firmed that human PBMC mediated significant cellular
cytotoxicity through the engagement of either anti-CCR7
(p = 0.0178) or alemtuzumab (p = 0.0175) (Figure 1D).
Anti-CCR7 mAb delays the appearance of tumors in an
early-treated subcutaneous model of mantle cell lymphoma
These in vitro results described above prompted us to
question whether the anti-CCR7 mAbs might also block
MCL cells migration towards the anatomic sites produ-
cing CCL19 and CCL21 and trigger MCL cells cell death
in vivo. To assess the in vivo effects of anti-CCR7 mAb,
Granta-519 MCL cells were xenografted in NOD/SCID
mice. Two models were studied: cells were inoculated
either subcutaneously or intravenously in the tail vein,
to produce either localized tumors or to generate diffuse
lymphoma in the mice over time. Also, the 150503 anti-
CCR7 mAb clone was used for these in vivo experiments
in virtue of its effectiveness inhibiting the in vitro migra-
tion of MCL cells and mediating CDC.
The subcutaneous model of MCL was generated by
subcutaneous implantation of 5 × 106 Granta-519 cells
in the right flank of NOD/SCID mice. To determine the
efficiency of the anti-CCR7 therapy in the early stages of
tumor implantation we established two groups of mice:
1) the treated group (n = 5), that received intraperitone-
ally 200 μg of anti-CCR7 mAb on days 2, 6 and 10 after
the Granta-519 cells inoculation, and 2) the control
group (n = 5), that was treated with PBS following the
same schedule than that of the treated group. The treat-
ment was stopped after day 10 because a significant
therapeutic effect was already observed. For comparative
reasons, all animals were sacrificed at day 27 as de-
scribed in materials and methods section. The first
measurable subcutaneous tumors were detectable at day
8 in the control mice (Figure 2A, day 8). In contrast, the
treatment with the anti-human CCR7 mAb significantly
delayed the tumor appearance and the first subcutane-
ous tumors were observed at day 17 in three out of five
mice (Figure 2A, day 17). Differences in tumor volume
were also observed between the two groups by the end
of the study (Figure 2A). Tumor growth inhibition was
evident until day 17 in the mice treated with anti-CCR7
mAb (Figure 2B), even though treatment was stopped at
day 10 post-inoculation. At the end-point of the study,
the size of the tumors in the untreated group was clearly
larger than that of the treated group (Figure 2A, day 27).
Mechanism of the in vivo tumoricidal activity of the
anti-human CCR7 mAb in the subcutaneous model
The delay in the tumor growth exerted by the anti-
human CCR7 mAb might involve the death of tumor
cells by cytotoxicity. To verify this hypothesis, Granta-
Figure 1 In vitro mechanisms of action of anti-CCR7 mAb. (A) Expression of CCR7 on MCL cell line Granta-519 by flow cytometry. Cells were
co-stained with anti-CD19 monoclonal antibody (mAb) and either isotype control mAb (grey area) or anti-human CCR7 mAb (white area). CCR7 surface
density was measured as mean fluorescence intensity (MFI). One representative experiment is shown. (B) Anti-CCR7 mAb abrogated the migration of
Granta-519 cells. Cells were preincubated with anti-CCR7 mAb (2 μg/ml) or the respective irrelevant isotype control and then exposed to CCL19 or
CCL21 for 4 hours in a transwell assay. (C) Anti-CCR7 mAb mediates specific CDC in Granta-519 cells. Cells were incubated with anti-CCR7 mAb (2 μg/ml)
or the respective irrelevant isotype control (IC) and then exposed to rabbit complement for 1 h. Cell lysis was determined by 7-AAD incorporation in flow
cytometry. The fold induction of cell lysis as a result of CDC is shown here. Bars represent mean +/− SD of six experiments. P-value refers to the difference
of cell lysis fold induction mediated by an IC or an anti-CCR7 mAb. (D) Anti-CCR7 mAb mediates ADCC of Granta-519 cells. Calcein-UV-labeled Granta-
519 cells previously incubated either with isotype control (IC), anti-CCR7 mAb (100 μg/ml) or alemtuzumab (100 μg/ml), were plated with human PBMC
at an effector to target ratio of 10:1 for 24 hours. The average percentage of specific lysis +/− SEM from three independent experiments is shown.
P-values refer to the differences of specific lysis mediated by anti-CCR7 mAb or alemtuzumab and the IC.
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tumors at the end of the experiment (day 27) and were
double stained with Annexin-V/7-AAD to assess cell
viability (Figure 3A). Interestingly, we observed a
significant increase in the percentage of non-viable cells
in the CCR7 mAb treated group when compared to the
control group (Figure 3B). This result supports the
notion that the anti-CCR7 mAb is able to induce in vivo
cytotoxicity probably mediated by NK cells as the NOD/
SCID mice lack functional complement and cytotoxic T
cells. Indeed, a significant ADCC activity was mediated by
splenocytes from NOD/SCID mice through the engage-
ment of the anti-CCR7 mAb causing Granta-519 MCL
cell death (Figure 3C). Confirming that ADCC was medi-
ated by NK cells, splenocytes from NSG mice, which are
completely devoid of NK and cytotoxic T cells, did
not induced significant ADCC in Granta-519 cells
(Figure 3C).Anti-human CCR7 mAb reduces dissemination of tumor
cells in distant organs in the subcutaneous model
The extent of tumor dissemination was assessed by flow
cytometry analysis of cell suspensions obtained from
spleen and bone marrow at 27 days after subcutanenous
implantation (Figure 4). Lymph nodes were nearly un-
detectable due to the immunodeficient status of the
NOD/SCID mice and the relatively short follow up of
the model. Interestingly enough, there was a significant
reduction (p = 0.018) in the number of the infiltrating
Granta-519 MCL (human CD20+) cells in the bone
marrow samples from the treated group (122 ± 25.5 per
million of total cells) compared to the number of infil-
trating tumor cells in the control group (384 ± 64.4 per
million of total cells). Infiltrating human CD20+ cells were
also reduced in the spleen of treated group (74 ± 35.6 per
million of total cells) compared to the control group
(261 ± 72.5 per million of total cells), although it did not
Figure 2 Anti-CCR7 mAb reduces tumor growth of MCL cells. Granta-519 cells were implanted subcutaneously in the right flank of NOD/SCID
mice (n = 10). Treatment started at day 2 post-inoculation and continued at days 6 and 10. Anti-CCR7 mAb were administered intraperitoneally.
Once subcutaneous tumors were palpable (≥4 mm) the diameters of the tumor mass was measured every 3 days. (A) Effect of anti-CCR7 mAb
treatment on tumor volume in Granta-519 xenograft-bearing mice. An altered growth pattern in the treated and control groups are shown in
the graph. The time points correspond to day 8 (first palpable tumors), day 17 and day 27. Each black dot (●, control group) or white square
(□, treated group) represents one individual mouse. Horizontal bars represent mean tumors volume of each group, which consisted of 5 mice.
Tumor volumes were calculated according to the V = D * d2/2 formula, as stated in Design and methods. P-values refer to the tumor volume
differences from mice treated with PBS or anti-CCR7 mAb at different time points. (B) Anti-CCR7 mAb delays the development of subcutaneous
tumors. The maximum growth inhibitory rate (IR) was reached within the first two weeks post anti-CCR7 mAb administration. The inhibitory rate
is shown and is given by IR(%) = 100 ‐ [(V1/V2)] * 100 where V1 is the mean tumors volume in the mAb treated groups and V2 is the mean tumors
volume in the control group.
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metastases in non-lymphoid organs was found in either
group of mice, which could be explained by the lack of
time for the cells to migrate into these other organs (data
not shown).Anti-CCR7 mAb prevents tumor growth in peri-implantation
and post-implantation Granta-519 MCL xenogratf models
The intravenous model of MCL with Granta-519 cells
is characterized by infiltration of different lymphoid or-
gans, mostly bone marrow, and of the CNS, in particular
Figure 3 Anti-human CCR7 mAb induces cell death in xenografted Granta-519 cells from the subcutaneous tumors. The Annexin-V-FITC/
7-AAD assay was used to quantitatively determine the percentage of non-viable cells following exposure to the anti-CCR7 mAb. (A) Granta-519
cells maintained in culture medium supplemented with 10% FCS (upper dot plot). Xenografted Granta-519 cells harvested from subcutaneous
tumors in the control group (middle dot plot). Xenografted Granta-519 cells recovered from subcutaneous tumors in the CCR7 mAb-treated
group (bottom dot plot). The Annexin V/7-AAD double staining made it possible to distinguish among viable cells (Annexin-V-/7-AAD-), early
apoptotic cells (Annexin-V+/7-AAD-), late apoptotic cells (Annexin-V+/7-AAD+) and dead cells (Annexin-V-/7-AAD+). A representative experiment
is shown (n = 5). (B) Percentage of dead cells (Annexin-V-/7-AAD+) in tumors from the control group (white bar, n = 5) or the treated group
(black bar, n = 5). The mean ± SEM is shown. P-value denotes significant differences between the percentage of dead cells in the subcutaneous
tumors from PBS- and anti-CCR7 mAb-treated mice. (C) Splenocytes from NOD/SCID mice but not from NSG mice mediate anti-CCR7 mAb-dependent
cellular cytotoxicity. Calcein-UV-labeled Granta-519 target cells previously incubated either with IC or anti-CCR7 mAb (100 μg/ml) were plated with
mice splenocytes at effector to target ratio of 10:1 for 24 hours. The mean percentage of specific lysis +/− SEM is shown from seven independent
experiments with NOD/SCID mice and three independent experiments with NSG mice. P-values refer to the differences between the specific death
mediated by the IC and the anti-CCR7 mAb in the corresponding strain of mice.
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sis of the xenografted mice. The mice in the control
group were all sacrificed between days 42 and 71 when
the first signs of hind leg paralysis were evident, with a
median survival time of 56 days. Remarkably, all micetreated with anti-CCR7 mAb starting 2 days after inocu-
lation (peri-implantation model) remained alive at the
time when the last mouse in the control group had to
be euthanized. These mice treated with the anti-CCR7
mAb did not develop any clinical sign and survived up
Figure 4 Anti-human CCR7 mAb reduces tumor cell infiltration in
bone marrow and spleen in the subcutaneous model of the MCL.
One million cells from spleen and bone marrow were harvested and
incubated with anti-human-CD20 mAb and the respective irrelevant
isotype control. Then, the number of xenografted Granta-519 cells
migrated to bone marrow and spleen in control mice (grey bar) and
treated mice (black bar) was quantified. The mean ± SE is shown.
P-values refer to the differences of infiltration in tissues from PBS- and
anti-CCR7 mAb-treated mice.
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a bona fide disease-free period (Figure 5A). At the
time of the sacrifice, between days 42 and 71 after in-
oculation in the untreated group and on day 120 in the
treated group, several tissues and cells from different
lymphoid organs were collected to study the degree of
lymphoma development and infiltration. In untreated
mice the percentage of positive CD20+ Granta-519
cells in bone marrow ranged from 8% to 71% whereas
in spleen was nearly undetectable (Figure 5B). Lymph
nodes were only found in two out of five control mice,
and these nodes were mainly populated by human CD20+
cells (data not shown). Conversely, there was a consist-
ent infiltration of certain non-lymphoid organs such as
the ovaries (Figure 5B), spinal cord, brain and lungs
(Figure 5C). In contrast, and consistent with the survival
data, we could not find any Granta-519 cells in the differ-
ent organs from mice treated with the anti-CCR7 mAb
(Figure 5B and C).
Due to the high therapeutic efficacy of the anti-CCR7
mAb described in this section, the potential of the anti-
body was further studied in a post-implantation disease
model in which surviving Granta-519 MCL cells might
have already migrated to their target organs and be less
exposed to the anti-CCR7 treatment, thus better repre-
senting a clinical scenario in humans. For this purpose,
the treatment was initiated seven days after the intraven-
ous inoculation of the lymphoma cells. In these new set
of experiments, three groups of five mice each were
treated with 200 μg of the anti-CCR7 mAb, 200 μg of itscorresponding IC or with PBS (the vehicle of administra-
tion), that were administered intraperitoneally on days 7,
11 and 15. The survival rate in both PBS and IC groups
was 20% with an average survival of 68 days in the PBS
group and 75 days in the IC group. Remarkably, 100% of
the mice treated with anti-CCR7 were alive after
6 months (Figure 6A). At the time of the sacrifice, be-
tween days 56 and 109 after inoculation in the IC group
and on day 180 in the treated group, several tissues were
collected and analyzed. Similar to the peri-implantation
disease model there was a constant infiltration of the
CNS and other distant organs including lungs, in both
the PBS and the IC groups, which was prevented by the
anti-CCR7 mAb (Figure 6B).Discussion
In this study, we provide preclinical proof of concept of
the efficacy of the anti-CCR7 therapy in a MCL model.
CCR7 mediates the classical chemotaxis and extravasa-
tion pathways of lymphoid cells into the targeted organs
but also it participates in cell invasion by promoting
extracellular matrix degradation through the secretion of
metalloproteases [28]. In addition, the ligands of CCR7
have been demonstrated to mediate prosurvival signals
in both epithelial and lymphoid neoplasias [20,29-31]. In
summary, the chemokine receptor CCR7 enables lymph-
oma cells to enter and disseminate in anatomic niches
where they received different pro-survival signals includ-
ing those from CCR7 ligands themselves [3]. For all these
reasons, therapeutic effects of anti-CCR7 mAbs would not
be restricted to classic complement or cellular-dependent
cytotoxicity, but also would imply the blockage of migra-
tion and invasive signals derived from the activated CCR7,
thus preventing lymphoma cells migration to lymphoma
supporting-niches.
Consistent with a critical role of CCR7-regulated cell
migration in lymphoma development, it has been de-
scribed that CCR7–deficient lymphoma cells have a sig-
nificant delay in the onset of lymphoma compared to
CCR7+ lymphoma cells [32]. Indeed, it was demon-
strated that such delay in lymphoma progression was re-
lated to the blockage of migratory signals evoked by
CCR7 since the absence of this chemokine receptor did
not alter the proliferative and/or apoptotic rates of the
CCR7−/− lymphoma cells.
The well-known role of tumor microenvironment as a
driver of tumor survival and promoter of drug resis-
tances turns it as a suitable target for pharmacology de-
velopment aimed to block stroma’s survival signals
driving the progression of the disease. Among those tar-
gets are CXCR4 antagonists [33], PI3K, Btk or Syk inhib-
itors [34,35], antibodies directed against CD44 [36] or
combined therapies [37].
Figure 5 Survival and organ infiltration in the peri-implantation model of disseminated MCL. (A) Anti-human CCR7 mAb significantly
increases the survival of xenografted mice. Kaplan-Meier estimates of overall survival of mice treated with the anti-CCR7 mAb. Granta-519 cells
were implanted intravenously in the vein tail of NOD/SCID mice (n = 10). Treatment with 200 μg of the anti-CCR7 mAb (■) or with PBS (●) started
at day 2 post-inoculation and continued at days 6 and 10. (B) and (C) Anti-human CCR7 mAb significantly reduces the infiltration of lymphoid
and distant organs. (B) One million cells from spleen, bone marrow and ovaries were harvested and incubated with anti-human-CD20 and the
respective irrelevant isotype control. Then the percentage of xenografted CD20+ Granta-519 cells migrated to bone marrow, spleen and ovaries
are shown. P-values refer to the differences of infiltration in tissues from PBS- and anti-CCR7 mAb-treated mice. Each black dot (●, control group)
or black square (■, treated group) represents one individual mouse. Horizontal bars represent mean percentage of xenografted CD20+ Granta-
519 cells of each group, which consisted of 5 mice. (C) Immunohistochemistry assays with anti-human CD20 mAb were performed in tissue
sections from brain, spine and lungs. Representative pictures from both a control mouse and an anti-CCR7- treated mouse are shown.
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Figure 6 Survival and organ infiltration in the post-implantation model of disseminated MCL. (A) Anti-human CCR7 mAb significantly
increases the survival of xenografted mice. Kaplan-Meier analysis of overall survival of mice treated with the anti-CCR7 mAb. Granta-519 cells were
implanted intravenously in the vein tail of NOD/SCID mice (n = 15). Treatment with 200 μg of either the anti-CCR7 mAb or its corresponding
isotype control or with PBS started at day 7 post-inoculation and continued at days 11 and 15. Anti-CCR7 mAb were administered intraperitoneally.
P-value refers to the differences of the survival of PBS-, IC- and anti-CCR7-treated groups (B) Anti-human CCR7 mAb significantly reduces the infiltration
of distant organs in the post-implantation model. Immunohistochemistry analyses were performed in tissue sections from brain, spine and lungs using
anti-human CD20 mAb. Representative pictures from both a control mouse and an anti-CCR7 treated mouse are shown.
Somovilla-Crespo et al. Journal of Hematology & Oncology 2013, 6:89 Page 11 of 14
http://www.jhoonline.org/content/6/1/89
Somovilla-Crespo et al. Journal of Hematology & Oncology 2013, 6:89 Page 12 of 14
http://www.jhoonline.org/content/6/1/89A combined anti-CCR7 therapy might include an anti-
CCR7 mAb and inhibitors of the signaling pathways ac-
tivated by the CCR7 ligands, including inhibitors of the
kinases PI3K, ROCK and ERK which efficiently block
both CCR7-mediated migration and survival ex vivo in
primary CLL cells from patients [20]. In the particular
case of the MCL, it is known that BCR-associated kinases
Syk and Btk are the most abundantly expressed phospho-
proteins [38], suggesting that BCR signaling plays a central
role in disease maintenance and progression. The inhibitors
of Syk and Btk have already entered the clinical stage [22].
It would be very interesting to investigate whether CCR7
blockage with anti-CCR7 mAbs would cooperate with these
kinases inhibitors to abrogate MCL growth and survival.
In our experiments mice were administered with
200 μg per inoculation (30 mg/m2). Considering that ri-
tuximab is given to patients at a dose of 375 mg/m2, a
therapy with anti-CCR7 seems feasible in human pa-
tients. Mice treated with this dosage of anti-CCR7 mAb
did not have any evident unwanted effect caused by the
treatment (with or without the inoculation of the lymph-
oma cells) even six months after the administration of
the anti-CCR7 mAb (data not shown). However, these
mice were immunodeficient, and further research is
required to assess whether an anti-CCR7 therapy could
result in any kind of immunodeficiency, since the anti-
CCR7 antibody could both eliminate normal naïve and
central memory lymphocytes and inhibit their entry into
SLO. However, if any immunodeficiency is triggered by
the anti-CCR7 therapy, it should be expected that while
it could be greater than that caused by the treatment
with rituximab, which only eliminates B cells, it would
be milder than that caused by alemtuzumab treatment,
which eliminates all T and B lymphocytes as well as
other leukocyte subpopulations [39,40].
On the other hand, an anti-CCR7 therapeutic strategy
would also eliminate or abrogate the migration of other
CCR7-expressing cell populations like natural regulatory
T cells or the semi-mature dendritic cells, which contrib-
ute to the induction and maintenance of the tolerance
[41,42]. In this regard, it has been published that the
chronic absence of CCR7 may lead to the development
of autoimmune diseases given the role of CCR7 in the
maintenance of the tolerance [43]. However, targeting
the CCR7 molecule on T cells during the limited period
of the therapeutic window may also overcome tumor
tolerance mediated by CCR7+ regulatory T cells, in
addition to both the tumoricidal effect exerted by the
anti-CCR7 mAb and the abrogation of the nodular dis-
semination and metastasis of tumors expressing this che-
mokine receptor. Moreover, it is worth mentioning that
blocking the entry of normal CCR7-positive T lymphocytes
into SLO may be beneficial because once inside the SLO
they support the growth of B cells either normal ortumoral, through certain costimulatory molecules such as
CD40L, which activates CD40 on the surface of B cells [44].
The beneficial effects of an anti-CCR7 therapy would
not be limited to the blocking of the migration of CCR7-
expressing cells towards SLO but also towards different
anatomic sites including CNS which represents one of
the most important sanctuaries of the hematological ma-
lignancies. For this reason, it would be very interesting
to identify those malignant hemopathies in which CCR7
expression correlates with CNS infiltration, as it is the
case for T-cell acute lymphoblastic leukemia [18]. It is
worth noting, however, that CLL, which is the chronic
lymphoproliferative disorder having the highest expres-
sion levels of CCR7, does not usually infiltrate neural tis-
sues. This suggests that other factors besides CCR7,
such as adhesion molecules and metalloproteases might
be involved in the colonization of CNS.
Apart from its role in the dissemination of
hematologic malignancies, CCR7 is responsible, at least
in part, for the ganglionar dissemination of solid epithe-
lial tumors including breast, colorectal, head and neck
and gastric carcinomas [45] as well as melanoma [46].
Unpublished results from our group indicate that the
activation of CCR7 in the breast cancer cell line MCF7
leads to the activation of the oncoprotein cortactin and
the promotion of cellular structures essential for metas-
tasis like lamellipodia and invadopodia. Interestingly,
the treatment with a blocking anti-CCR7 mAb abro-
gated both lamellipodia and invadopodia formation,
further supporting the role of CCR7-mediated signaling
in cancer progression.
In our current study, the mice with the subcutaneous
lymphoma that were treated with the anti-CCR7 mAb
developed substantially less metastasis to distant organs
when compared with the untreated mice suggesting a
potential therapeutic role to prevent metastasis in those
primary tumors expressing this chemokine receptor.
Further studies to demonstrate an antimetastatic effect
of the anti-CCR7 therapy in an ortothopic model of
breast carcinoma with MCF7 cells are warranted.
In conclusion, the data presented here demonstrate
that the anti-CCR7 mAb has a notable anti-tumor effi-
cacy, causing a significant delay of the tumor growth
rate and metastatic process in the subcutaneous model
and also hindering lymphoma cells dissemination in the
intravenous model. Our results support that anti-CCR7
therapy might be indicated for patients suffering of
CCR7-positive B cell non-Hodgkin lymphoma and CLL.
Our study open a way for the development of different
therapeutic protocols in which the current chemother-
apy could be used in combination with antagonists of
either CCR7 expression or function, including anti-CCR7
mAbs and pharmacologyc inhibitors of CCR7-signaling
pathways.
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Additional file 1: Figure S1. Expression of CCR7 in different B cell
malignancies. Surface CCR7 expression of different B cell neoplasms was
analyzed by flow cytometry and expressed as percentage of CCR7+ cells
(A) or as the MFI of CCR7-positive cells (B). Normal B cells (n = 4); B-cell
acute lymphoblastic leukemia (B-ALL) (n = 3); Mantle cell lymphoma
(MCL) (n = 6); Follicular lymphoma (FL) (n = 9); Splenic marginal zone
lymphoma (SMZL) (n = 3); Hairy cell leukemia (HCL) (n = 4); Lymphoplas-
macytic lymphoma (LPL) (n = 9); Multiple myeloma (MM) (n = 10);
atypical CD5- B-cell chronic lymphocytic leukemia (CD5- B-CLL) (n = 5);
typical CD5+ B-cell chronic lymphocytic leukemia (CD5+ B-CLL) (n = 79).
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